Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIb, Randomised, Double-blind, Placebo-controlled, Multi-centre Trial of Infliximab With Transcriptomic Biomarker and Mechanism Evaluation in Patients With Acute Pancreatitis.

NCT03684278 is registered in ClinicalTrials.gov with University of Liverpool as lead sponsor.

NCT NCT03684278
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03684278 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIb, Randomised, Double-blind, Placebo-controlled, Multi-centre Trial of Infliximab With Transcriptomic Biomarker and Mechanism Evaluation in Patients With Acute Pancreatitis.
Lead sponsor
University of Liverpool
Phase
Phase 2
Overall status
Recruiting
Start date
May 1, 2019
Completion date
March 6, 2027
Enrollment
240 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

acute pancreatitis